Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reparixin in Hospitalized Patients With COVID-19 and CAP
NCT05254990Phase 3Terminated
- Sponsor
- Dompé
- Start
- Apr 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of reparixin in community acquired pneumonia (CAP), coronavirus disease 2019 (COVID-19), sponsored by Dompé. Started Apr 2022; status: terminated.
02
Drugs
reparixin
03
Conditions
community acquired pneumonia (CAP)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05254990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05254990.